Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer | Zendy

Maryse Brassard | Zendy; B. Néraud | Zendy; Séverine Trabado | Zendy; Sylvie Salenave | Zendy; Sylvie BraillyTabard | Zendy; Isabelle Borget | Zendy; Éric Baudin | Zendy; Sophie Leboulleux | Zendy; Philippe Chanson | Zendy; Martin Schlumberger | Zendy; Jacques Young | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer

Author(s) -

Maryse Brassard,

B. Néraud,

Séverine Trabado,

Sylvie Salenave,

Sylvie BraillyTabard,

Isabelle Borget,

Éric Baudin,

Sophie Leboulleux,

Philippe Chanson,

Martin Schlumberger,

Jacques Young

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2010-2771

Subject(s) - medicine , endocrinology , vandetanib , placebo , endocrine system , vitamin d and neurology , hormone , thyroid , testosterone (patch) , tyrosine kinase , receptor , alternative medicine , pathology

The purpose of the study was to assess the endocrine effects of vandetanib, a multikinase inhibitor targeting RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor, in 39 patients with progressive thyroid cancer included in two randomized placebo-controlled trials using vandetanib 300 mg/d.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research